UNLABELLED: Altered gut microbiome is associated with systemic inflammation and cirrhosis decompensation. However, the correlation of the oral microbiome with inflammation in cirrhosis is unclear. Our aim was to evaluate the oral microbiome in cirrhosis and compare with stool microbiome. Outpatients with cirrhosis (with/without hepatic encephalopathy [HE]) and controls underwent stool/saliva microbiome analysis (for composition and function) and also systemic inflammatory evaluation. Ninety-day liver-related hospitalizations were recorded. Salivary inflammation was studied using T helper 1 cytokines/secretory immunoglobulin A (IgA), histatins and lysozyme in a subsequent group. A total of 102 patients with cirrhosis (43 previous HE) and 32 age-matched controls were included. On principal component analysis (PCA), stool and saliva microbiome clustered far apart, showing differences between sites as a whole. In salivary microbiome, with previous HE, relative abundance of autochthonous families decreased whereas potentially pathogenic ones (Enterobacteriaceae, Enterococcaceae) increased in saliva. Endotoxin-related predicted functions were significantly higher in cirrhotic saliva. In stool microbiome, relative autochthonous taxa abundance reduced in previous HE, along with increased Enterobacteriaceae and Enterococcaceae. Cirrhotic stool microbiota demonstrated a significantly higher correlation with systemic inflammation, compared to saliva microbiota, on correlation networks. Thirty-eight patients were hospitalized within 90 days. Their salivary dysbiosis was significantly worse and predicted this outcome independent of cirrhosis severity. Salivary inflammation was studied in an additional 86 age-matched subjects (43 controls/43 patients with cirrhosis); significantly higher interleukin (IL)-6/IL-1β, secretory IgA, and lower lysozyme, and histatins 1 and 5 were found in patients with cirrhosis, compared to controls. CONCLUSIONS: Dysbiosis, represented by reduction in autochthonous bacteria, is present in both saliva and stool in patients with cirrhosis, compared to controls. Patients with cirrhosis have impaired salivary defenses and worse inflammation. Salivary dysbiosis was greater in patients with cirrhosis who developed 90-day hospitalizations. These findings could represent a global mucosal-immune interface change in cirrhosis.
UNLABELLED: Altered gut microbiome is associated with systemic inflammation and cirrhosis decompensation. However, the correlation of the oral microbiome with inflammation in cirrhosis is unclear. Our aim was to evaluate the oral microbiome in cirrhosis and compare with stool microbiome. Outpatients with cirrhosis (with/without hepatic encephalopathy [HE]) and controls underwent stool/saliva microbiome analysis (for composition and function) and also systemic inflammatory evaluation. Ninety-day liver-related hospitalizations were recorded. Salivary inflammation was studied using T helper 1 cytokines/secretory immunoglobulin A (IgA), histatins and lysozyme in a subsequent group. A total of 102 patients with cirrhosis (43 previous HE) and 32 age-matched controls were included. On principal component analysis (PCA), stool and saliva microbiome clustered far apart, showing differences between sites as a whole. In salivary microbiome, with previous HE, relative abundance of autochthonous families decreased whereas potentially pathogenic ones (Enterobacteriaceae, Enterococcaceae) increased in saliva. Endotoxin-related predicted functions were significantly higher in cirrhotic saliva. In stool microbiome, relative autochthonous taxa abundance reduced in previous HE, along with increased Enterobacteriaceae and Enterococcaceae. Cirrhotic stool microbiota demonstrated a significantly higher correlation with systemic inflammation, compared to saliva microbiota, on correlation networks. Thirty-eight patients were hospitalized within 90 days. Their salivary dysbiosis was significantly worse and predicted this outcome independent of cirrhosis severity. Salivary inflammation was studied in an additional 86 age-matched subjects (43 controls/43 patients with cirrhosis); significantly higher interleukin (IL)-6/IL-1β, secretory IgA, and lower lysozyme, and histatins 1 and 5 were found in patients with cirrhosis, compared to controls. CONCLUSIONS:Dysbiosis, represented by reduction in autochthonous bacteria, is present in both saliva and stool in patients with cirrhosis, compared to controls. Patients with cirrhosis have impaired salivary defenses and worse inflammation. Salivary dysbiosis was greater in patients with cirrhosis who developed 90-day hospitalizations. These findings could represent a global mucosal-immune interface change in cirrhosis.
Authors: Ruggiero Francavilla; Danilo Ercolini; Maria Piccolo; Lucia Vannini; Sonya Siragusa; Francesca De Filippis; Ilaria De Pasquale; Raffaella Di Cagno; Michele Di Toma; Giorgia Gozzi; Diana I Serrazanetti; Maria De Angelis; Marco Gobbetti Journal: Appl Environ Microbiol Date: 2014-03-21 Impact factor: 4.792
Authors: Jasmohan S Bajaj; Patrick M Gillevet; Neeral R Patel; Vishwadeep Ahluwalia; Jason M Ridlon; Birgit Kettenmann; Christine M Schubert; Masoumeh Sikaroodi; Douglas M Heuman; Mary M E Crossey; Debulon E Bell; Philip B Hylemon; Panos P Fatouros; Simon D Taylor-Robinson Journal: Metab Brain Dis Date: 2012-04-12 Impact factor: 3.584
Authors: Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li Journal: Nature Date: 2014-07-23 Impact factor: 49.962
Authors: Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet Journal: PLoS One Date: 2013-04-02 Impact factor: 3.240
Authors: Derek S Borgwardt; Aaron D Martin; Jonathan R Van Hemert; Jianyi Yang; Carol L Fischer; Erica N Recker; Prashant R Nair; Robinson Vidva; Shwetha Chandrashekaraiah; Ann Progulske-Fox; David Drake; Joseph E Cavanaugh; Shireen Vali; Yang Zhang; Kim A Brogden Journal: Sci Rep Date: 2014-01-29 Impact factor: 4.379
Authors: Jasmohan S Bajaj; Payam Matin; Melanie B White; Andrew Fagan; Janina Golob Deeb; Chathur Acharya; Swati S Dalmet; Masoumeh Sikaroodi; Patrick M Gillevet; Sinem E Sahingur Journal: Am J Physiol Gastrointest Liver Physiol Date: 2018-08-17 Impact factor: 4.052
Authors: Jasmohan S Bajaj; Masoumeh Sikaroodi; Andrew Fagan; Douglas Heuman; HoChong Gilles; Edith A Gavis; Michael Fuchs; Javier Gonzalez-Maeso; Shahzor Nizam; Patrick M Gillevet; James B Wade Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-08-28 Impact factor: 4.052